Peng Cheng-Yuan, Chen Tse-Ching, Hung Shao-Pi, Chen Miin-Fu, Yeh Chau-ting, Tsai Sun-Lung, Chu Chia-Ming, Liaw Yun-Fan
Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University, Tao Yuan, Taiwan.
Anticancer Res. 2002 Mar-Apr;22(2B):1265-71.
The INK4alpha/ARF locus encodes p14(ARF) and p16(INK4alpha) , that function to arrest the cell cycle through the p53 and RB pathways, respectively. Genetic alterations of p14ARF and their relationship with p16(INK4a) or p53 inactivation have not been characterized in hepatocellular carcinoma (HCC). We examined 40 pairs of HCCs/noncancerous liver tissues for homozygous deletions (HD), methylation and mutations of the INK4a/ARF locus and for mutations of p53, and analyzed their clinicopathological correlation. p16(INK4a), p53 and p14(ARF) were inactivated in 62.5% (25 out of 40), 42.5% (17 out of 40) and 20% (8 out of 40) of HCCs, respectively. Inactivation of p14(ARF) was always associated with the concomitant inactivation of p16(INK4a) and occurred more frequently in hepatitis C virus (HCV)-associated HCC (p=0.042). Inactivation of p16INK4a) occurred more frequently in older patients (p=0.0027. The predominant mechanism of inactivation of p14(ARF) was homozygous deletion (7 out of 8), while that of p16(INK4a) was methylation (21 out of 25). Although statistically insignificant, genetic alterations of p14(ARF) tended to occur in tumors with wild-type p53. Genetic alterations of the INK4alpha/ARF locus could occur in small HCCs. In contrast, p53 mutations occurred more frequently in advanced HCCs (p=0.041). Inactivation of either p14(ARF)/p53 or p16(INK4a) occurred in 80% (32 out of 40) and concomitant disruption of both pathways occurred in 40% (16 out of 40) of HCCs, respectively. These results suggest that p14(ARF), p16(INK4a) and p53 are differentially disrupted through distinct molecular mechanisms at different stages in HCC and that p14(ARF) and p53 appear to function in the same tumor suppression pathway in HCC
INK4alpha/ARF基因座编码p14(ARF)和p16(INK4alpha),它们分别通过p53和RB途径发挥作用来阻止细胞周期。在肝细胞癌(HCC)中,p14ARF的基因改变及其与p16(INK4a)或p53失活的关系尚未得到明确阐述。我们检测了40对HCC/非癌肝组织中INK4a/ARF基因座的纯合缺失(HD)、甲基化和突变情况以及p53的突变情况,并分析了它们与临床病理的相关性。在40例HCC中,p16(INK4a)、p53和p14(ARF)的失活率分别为62.5%(40例中的25例)、42.5%(40例中的17例)和20%(40例中的8例)。p14(ARF)的失活总是与p16(INK4a)的伴随失活相关,并且在丙型肝炎病毒(HCV)相关的HCC中更频繁发生(p = 0.042)。p16INK4a)的失活在老年患者中更频繁发生(p = 0.0027)。p14(ARF)失活的主要机制是纯合缺失(8例中的7例),而p16(INK4a)失活的主要机制是甲基化(25例中的21例)。虽然无统计学意义,但p14(ARF)的基因改变倾向于发生在p53野生型的肿瘤中。INK4alpha/ARF基因座的基因改变可发生在小肝癌中。相反,p53突变在进展期HCC中更频繁发生(p = 0.041)。在40例HCC中,p14(ARF)/p53或p16(INK4a)的失活分别发生在80%(40例中的32例),两种途径同时破坏发生在40%(40例中的16例)。这些结果表明,在HCC的不同阶段,p14(ARF)、p16(INK4a)和p53通过不同的分子机制受到不同程度的破坏,并且p14(ARF)和p53似乎在HCC的同一肿瘤抑制途径中发挥作用